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ABSTRACT
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. There are several treatment 
modalities according to Barcelona treatment algorithm. Liver transplant is one of the curative option treatments, 
with its indication and prognostic factors. Carefully selected patients for liver transplant in HCC case will result 
in the same or slightly inferior survival rate compare with liver transplant in non-malignancy case. 
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ABSTRAK
Karsinoma hepatoseluler (KHS) adalah jenis kanker hati tersering. Terdapat beberapa modalitas terapi 
pada KHS menurut algoritme terapi Barcelona. Transplantasi hati adalah salah satu modalitas terapi kuratif 
dengan indikasi dan factor prognostic tersendiri. Pemilihan pasien yang cermat untuk transplantasi hati pada 
kasus KHS akan menghasilkan tingkat ketahanan hidup yang sama atau sedikit lebih rendah dibandingkan 
transplantasi hati pada kasus bukan keganasan.
Kata kunci: transplantasi hati, karsinoma hepatoselular, indikasi, faktor prognosis
INTRODUCTION
Hepatocellular carcinoma (HCC) is an aggressive 
tumor in the course of chronic liver disease and 
cirrhosis. It is usually late diagnosed and has poor 
median survival rate, with average of 8 months.1 The 
optimal treatment modality is resection in non-cirrhotic 
or minimal cirrhosis patient and liver transplant in 
advanced cirrhotic patient. Unfortunately, majority 
of the patients are not suitable for liver transplant due 
to tumor metastasis, liver dysfunction, and shortage 
of donor organs. Therefore some experts developed 
various methods for local tumor ablation. 
There are some treatment options for local HCC. 
A treatment algorithm was published by Barcelona 
study (Figure 1).2 Liver transplant for HCC treatment 
is interesting since the cancer resection can be done 
together with cirrhotic liver replacement. However, 
the result of early studies of liver transplant in local 
HCC was disappointing. It had a high 90-day mortality 
rate, up to 80% tumor recurrence rate, and low long 
term survival rate compared with organ transplant in 
RWKHUPDOLJQDQF\FDVHVZKLFKUHÀHFWHGWKHQDWXUHRI
the disease.3,4
The philosophy of liver transplant in HCC has 
FKDQJHGGXHWR¿QGLQJWKDW+&&SDWLHQWZLWKVPDOO
nodule undergoing liver transplant had similar survival 
rate compared with liver transplant in non-malignant 
case.5 Moreover, there were increasing retrospective 
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studies showed liver transplant was one of the effective 
option and might be more effective than other therapies 
in some group of patients.
INDICATION 
Early study by Mazzaferro in 1996 emphasized 
cadaver donor for liver transplant (orthotopic liver 
transplant, OLT) was a good treatment for HCC.6 
It showed that liver transplant to early stage HCC 
VLQJOHOHVLRQFPXSWRVHSDUDWHOHVLRQVVPDOOHU
than 3 cm, no evidence of vascular invasion, and no 
regional node involvement or distant metastasis) had 
75% overall actuarial four-year survival rate and 83% 
four-year recurrence-free survival rate (Figure 2). This 
criteria were then widely known as Milan criteria and 
had been applied in all over the world in selecting HCC 
patients for liver transplant candidates.6 
HCC: hepatocellular carcinoma; PST: performance status; RFA: radio frequency ablation; TACE: transarterial chemoembolization
Figure 1. The Barcelona staging system and treatment algorithym2
Figure 2. Overall survival (panel A) and recurrence-free survival (panel B) after liver transplantation6
Volume 16, Number 2, August 2015 101
Liver Transplant in Hepatocellular Carcinoma: Indication and Prognostic Factors 
SURVIVAL RATE IN HCC LIVER TRANSPLANT
The survival rate of OLT in carefully selected 
HCC patients was the same or slightly lower than 
OLT in non-malignant patients.7 Report from the 
United Network for Organ Sharing (UNOS) focused 
on 34,324 liver transplantation cases done between 
1987 and 2001; 985 of which were done due to HCC.8 
7KH¿YH\HDUVXUYLYDOUDWHRI2/7LQ+&&LQFUHDVHG
VLJQL¿FDQWO\  DQG UHVSHFWLYHO\ LQ
the 3 different periods (1987-1991, 1992-1995, 1996-
2001) although the average waiting time to get the liver 
donor was increased (37 days, 103 days, 215 days, 
UHVSHFWLYHO\1HYHUWKHOHVVWKH¿YH\HDUVXUYLYDOUDWH
of OLT for non-malignancy indication was 71% with 
no changes over the study period. This study showed 
that a better outcome of OLT in HCC patients was more 
likely due to improvement in patient selection rather 
than technique and post transplant care. 
SURVIVAL RATE IN COMPARISON WITH OTHER 
TREATMENT MODALITIES
No random large scale studies directly comparing 
OLT with other type of treatments for early HCC. 
For anatomically operable HCC with adequate 
liver reserve, resection is the standard method to be 
compared with other treatment modalities. Some 
observational studies showed long term outcome after 
liver transplant was at least the same of slight superior 
than resection in some groups.9-13
The report from Pittsburgh including 181 HCC 
patients, of which 105 patients underwent OLT and the 
rest had liver resection.10 After 37 to 53 months of follow 
XS WKHUHZDVQRVLJQL¿FDQWGLIIHUHQW LQVXUYLYDO UDWH
of both groups if non-cirrhosis patients were included. 
However, when HCC was associated with cirrhosis of 
WKHOLYHUWKHVXUYLYDOUDWHVDIWHU2/7ZHUHVLJQL¿FDQWO\
better than those after resection at each stage of 
FODVVL¿FDWLRQ6LPLODUUHVXOWZDVIRXQGLQDVWXG\ZLWK
102 HCC patients, 50 patients of which underwent liver 
transplant and 52 patients had liver resection.14 Three-
year survival rate and recurrence rate was similar in 
both groups. However, OLT was associated with better 
three-year survival rate in cirrhosis patients (48% vs. 
23%) and patients having tumor greater than 3 cm (76% 
vs. 33%). Other study in 120 cirrhotic HCC patients 
showed similar result.12 Groups of patients in this study 
had the same underlying disease criteria, age, and tumor 
size. The rate for survival without recurrence was better 
in liver transplant group than resection group (46% vs. 
27%). In patients with small uninodular or binodular 
tumors (less than 3 cm), transplantation had better 
outcome than resection (survival without recurrence, 
83% vs. 18%). Transplantation also recommended in 
a study of 533 HCC patients with different treatments: 
OLT, resection, transarterial chemoembolization 
(TACE), percutaneus ethanol injection (PEI).11 Analysis 
was done based on number of lesion, stadium of the 
disease, alphafetoprotein (AFP) level, Child-Pugh lass, 
etiology of cirrhosis. Survival rate was better in patient 
undergoing OLT compared with other treatments (three-
\HDUDQG¿YH\HDUVXUYLYDOUDWHZHUHDQGIRU
OLT, 64% and 44% for resection, 54% and 36% for PEI, 
32% and 22% for TACE). OLT seemed to be treatment 
of choice for HCC patients having monofocal lesion less 
WKDQFP$OWKRXJKPDQ\VWXGLHVVKRZHGWKHEHQH¿WRI
liver transplant, especially in cirrhosis patient with small 
tumor, the number of HCC patients who are candidates 
for OLT and truly accept graft (no graft rejection) are 
very small.
For patients having HCC which are not candidate 
for resection, OLT is the suitable strategy for patients 
with single nodule less or equal than 5 cm, up to 3 
separate lesions smaller than 3 cm in size and no 
evidence of vascular invasion, no regional node 
involvement or distant metastasis. If the criteria are 
VWULFWO\DSSOLHGRIKLJKHURI¿YH\HDUVXUYLYDO
can be achieved. Survival rate for OLT in carefully 
selected HCC patients is the same or slightly inferior 
than OLT in non-malignant case. Although random trial 
is not available yet, some uncontrolled studies showed 
that survival rate in patients having OLT was good or 
better than other treatment modalities in HCC patients 
with some criteria.
PROGNOSTIC FACTOR
6RPH VWXGLHV KDG LGHQWL¿HG YDULDEOHV LQYROYLQJ
patients and tumor which were associated with 
prognosis after OLT in HCC.9,10,12-25 Some important 
factors were the number, size, location of tumor, 
GLVHDVHVWDGLXPDFFRUGLQJWRPRGL¿HG$PHULFDQ/LYHU
Tumor Study Group (ALTSG) (Table 1), histological 
differentiation grade, macro and microvascular 
invasion, and extrahepatic metastasis. The most 
consistent association was shown in the size of tumor.13
However, we have to remember that majority 
of the result here was based on analysis of patients 
undergoing liver transplant and not included all HCC 
patients eligible for liver transplant but died before 
the transplantation. Thus, the result depends on the 
short waiting time between diagnosis and actual 
transplantation. 
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The underlying etiology might become selection 
criterion for OLT. Patients with chronic hepatitis C 
virus (HCV) infection needed OLT for HCC more 
frequently than patients with chronic hepatitis B virus 
(HBV) infection. HCC patients with chronic HBV 
infection might be candidate for resection based on 
liver function and better tumor individual characteristic 
compared with chronic HCV infection. Since HCV 
patients had worse clinical condition and liver function, 
they had higher recurrence rate and shorter survival rate 
after resection or OLT in comparison with cirrhosis 
HBV patients or alcohol-induced HCC patients.26
IMMUNOSUPPRESSIVE AND ADJUVANT 
TREATMENT
Since immunosuppressive drug had been associated 
with higher risk of tumor recurrence, efforts were done 
to reduce the dose to the minimum effective dose.27,28 
This approach was suggested in a retrospective 
study in 70 patients undergone OLT for HCC receiving 
cyclosporine (CSA) based immunosuppressant drug.28 
6HUXP&6$ZDV VLJQL¿FDQWO\KLJKHU LQ WKRVHKDYLQJ
tumor recurrence compared with free tumor recurrence 
(278 vs. 170 ng/mL, respectively). ROC analysis 
LGHQWL¿HGQJP/DVDQRSWLPDOFXWRIIYDOXHKLJKHU
exposure increased the recurrence rate to 33% (7 from 21 
patients) compared with none of the 49 patients having 
lower serum level of CSA. Immunosuppressive agent 
with promising prospect in HCC transplant patient was 
sirolimus. In vivo study showed this agent could prevent 
the development of some tumor, included HCC.29 In a 
retrospective study in 40 HCC liver transplant patients 
PHWWKH0LODQFULWHULD WKHUHVWZDVFODVVL¿HGDV
“extended” criteria), sirolimus based immunosuppressive 
protocol seemed to have acceptable toxicity and rejection 
rate.30 Four year disease-free survival rate was better (81% 
and 77% for patients met Milan criteria and extended, 
respectively) compared with other studies. Although this 
data was promising, more data on long term successful 
rate of sirolimus based immunosuppressive therapy and 
toxicity were still needed. 
Adjuvant therapy after OLT has not been well 
studied.31 Theoretically, adjuvant therapy may be 
helpful for patients undergoing OLT since the liver 
resection process involves extensive manipulation and 
may spread the tumor intra operatively. Moreover, the 
immunosuppressive therapy might facilitate tumor 
growth resulting in post transplant tumor recurrence. 
$VWXG\UHSRUWHGVLJQL¿FDQWO\VKRUWHUWXPRUGRXEOLQJ
time in post OLT patients compared with post resection 
patients (40 days vs. 270 days).15 Some uncontrolled 
studies had suggested the benefit of adjuvant 
chemotherapy post OLT in HCC. However, in a 60 
patients case control study, chemotherapy (doxorubicin 
given as single agent to be given pre, intra, and post 
RSHUDWLYHO\ZDVQRWDVVRFLDWHGZLWKVLJQL¿FDQWEHWWHU
¿YH\HDUVXUYLYDOUDWHYV31
Moreover, there was a question regarding the 
harmful effect of chemotherapy associated with 
recurrence of HCV. In a study of 48 patients undergoing 
OLT for HCC, 21 patients got chemotherapy and 
27 patients did not get chemotherapy. The three-
month, six-month, and twelve-month disease-free 
survival rate were 29%, 14%, and 0% respectively in 
chemotherapy group compared with 76%, 38%, and 
25% respectively in no chemotherapy group.32 On the 
other hand, promising result was reported by a small 
placebo controlled, double blind study in China using 
radioimmunologic agent (Licartin, a 131-I-radiolabeled 
PXULQHPRQRFORQDODQWLERG\WDUJHWLQJVSHFL¿F+&&
molecule HAb18G/CD147).33 Sixty patients having 
pre transplant biopsy positive of HAb18G/CD147 
immunohistochemistry expression were randomly 
given 3 doses of monthly Licartin or placebo injection 
started 4 weeks after OLT. In 12 months follow up, 
/LFDUWLQJURXSKDGVLJQL¿FDQWUHGXFWLRQRIUHFXUUHQW
rate (27% vs. 57% in a year) and survival rate (83 vs. 
62% in a year). No special side effect occurred in the 
study. Further study with longer duration and greater 
VDPSOHVL]HDUHQHHGHGSULRUFRQFOXGLQJ WKHEHQH¿W
of Licartin post OLT. Due to low successful rate and 
risk of HCV recurrence, systemic adjuvant therapy 
is not recommended for patients undergoing liver 
transplantation for HCC, except in clinical trial. 
)LJXUH$PHULFDQ/LYHU7XPRU6WXG\*URXS$/76*PRGL¿HG
WXPRUQRGHPHWDVWDVLV710VWDJLQJFODVVL¿FDWLRQ17
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CONCLUSION
OLT is a curative treatment option in selected HCC 
patients, consisted of cadaver donor and live donor. 
The survival rate and disease recurrence rate after 
OLT in selected patients were the same or slightly 
inferior than other patients undergoing OLT for non 
malignant indication. Moreover, some retrospective 
studies showed post OLT survival rate was the same 
or better compared with other modalities.
Indication for OLT are not candidate for resection, 
having a single lesion less or equal than 5 cm, less 
than 3 separate lesions with less or equal than 3 cm, no 
vascular involvement, no regional node involvement 
RUGLVWDQWPHWDVWDVLV7KH¿YH\HDUVXUYLYDOUDWHPD\
increase up to 75% if the criteria are met. 
Prognostic factors for the success of liver transplant 
are the number, size, and location of tumor (especially 
bilobar distribution), disease stadium according to 
PRGL¿HG$/76*KLVWRORJLFDO GLIIHUHQWLDWLRQJUDGH
macro and microvascular invasion, and extrahepatic 
metastasis.
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